Aytu BioPharma, Inc.

NasdaqCM AYTU

Aytu BioPharma, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: -10.26%

Aytu BioPharma, Inc. Return on Capital Employed (ROCE) is -10.26% for the Trailing 12 Months (TTM) ending September 30, 2024, a 61.29% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Aytu BioPharma, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -26.49%, a 24.29% change year over year.
Aytu BioPharma, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -34.99%, a -17.04% change year over year.
Aytu BioPharma, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -29.90%, a -42.21% change year over year.
Aytu BioPharma, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -21.02%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: AYTU

Aytu BioPharma, Inc.

CEO	Mr. Joshua R. Disbrow
IPO Date	Sept. 25, 2008
Location	United States
Headquarters	373 Inverness Parkway
Employees	102
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Key trends

Past 5 years